• We use cookies to help make our website work. LEARN MORE

XenoGesis


You can delete your alerts anytime

XenoGesis Ltd. specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitropharmacology and modelling & simulation for human PK and dose prediction. The core XenoGesis team has a proven track record of delivery in drug discovery.

Through a consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for R&D companies. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.

The organisation combines its state-of-the-art in vitro, in vivo and bioanalytical capabilities with its expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services. Their laboratory tests demonstrate how the human body might affect the way a drug behaves, backed-up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’, which are what make the XenoGesis service attractive to global drug companies.

XenoGesis is a laboratory-based contract research organisation (CRO) based at BioCity in Nottingham and its Founder and Managing Director is Dr Richard Weaver. In 2018, XenoGesis opened a satellite office in Alderley Park and moved its head office into the state-of-the-art Discovery Building at BioCity in Nottingham.


Address:
BioCity
Pennyfoot Street
Nottingham
NG1 1GF

Phone: 0115 837 0626

Website: XenoGesis